Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 5:47 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 254 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Maximum Tolerated Dose Clear all

Conditions: Advanced Soft Tissue Sarcoma
Interventions: [Ac 225]RTX-2358, [Cu64]LNTH-1363S; Drug · Diagnostic Test
Lead sponsor: Ratio Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 5
States / cities: Los Angeles, California • Rochester, Minnesota • New York, New York + 2 more

Conditions: Cancer
Interventions: TAK-285 Dose Escalation Cohorts, TAK-285 Recommended Phase 2 Dosing Cohort; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 3
States / cities: Indianapolis, Indiana • Baltimore, Maryland • Detroit, Michigan

Conditions: Carcinoma
Interventions: Sorafenib 100 mg (50-mg tablet), Sorafenib 200 mg (50-mg tablet), Sorafenib 400 mg (50-mg tablet), Sorafenib 400 mg (200-mg tablet), Sorafenib 400 mg (Expansion); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 3
States / cities: Philadelphia, Pennsylvania • Nashville, Tennessee • Madison, Wisconsin

Conditions: Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Azacitidine Injection, sodium phenylbutyrate; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 120 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2005
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Locally Advanced/Metastatic HER2 Positive Solid Tumors
Interventions: BB-1701; Drug
Lead sponsor: Bliss Biopharmaceutical (Hangzhou) Co., Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 3
States / cities: San Francisco, California • Nashville, Tennessee • Fairfax, Virginia

Conditions: Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma
Interventions: Bapotulimab (BAY1905254), Bapotulimab (BAY1905254) + Pembrolizumab (KEYTRUDA®); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 8
States / cities: Tucson, Arizona • New Haven, Connecticut • Chicago, Illinois + 5 more

Conditions: Advanced Solid Tumors
Interventions: Elimusertib (BAY1895344), Pembrolizumab (Keytruda®); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 8
States / cities: Palo Alto, California • New Haven, Connecticut • Baltimore, Maryland + 5 more

Conditions: Small Cell Lung Carcinoma
Interventions: Roniciclib (BAY1000394), Etoposide, Cisplatin, Carboplatin; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 3
States / cities: St Louis, Missouri • Buffalo, New York • Cleveland, Ohio

Conditions: Multiple Myeloma
Interventions: BT062; Drug
Lead sponsor: Biotest Pharmaceuticals Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 5
States / cities: Atlanta, Georgia • Chicago, Illinois • Boston, Massachusetts + 2 more

Conditions: Advanced Solid Tumors
Interventions: BAY2965501, Pembrolizumab, Platinum-based Chemotherapy; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 284 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 3
States / cities: Denver, Colorado • Pittsburgh, Pennsylvania • San Antonio, Texas

Conditions: Hematologic Malignancies
Interventions: Clofarabine, Stem Cell Transplantation, Hematopoietic, OKT3, Thiotepa, Melphalan, Mycophenolate mofetil, Rituximab, G-CSF; Drug · Procedure · Other
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Advanced Solid Tumors
Interventions: ON 01910.Na and irinotecan, ON 01910.Na and oxaliplatin; Drug
Lead sponsor: Traws Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: L-778,123, paclitaxel; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2000
U.S. locations: 1
States / cities: New York, New York

Conditions: Adrenocortical Carcinoma (ACC), Recurrent Adrenocortical Carcinoma (ACC), Recurrent Abdominal Adrenocortical Carcinoma (ACC), Carcinoma, Adrenocortical, Carcinoma, Adrenal Cortical
Interventions: Surgical resection, Preoperative RT; Procedure · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2040
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: gemcitabine hydrochloride, tipifarnib; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2002
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Rheumatoid Arthritis
Interventions: AIN457, Placebo; Biological · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 12
States / cities: Anniston, Alabama • Tucson, Arizona • Largo, Florida + 9 more

Conditions: Ependymoma, High Grade Gliomas
Interventions: Rhenium-186 Nanoliposome; Drug
Lead sponsor: Cerenome; Industry
Eligibility: 6 Years to 21 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Leukemia
Interventions: Ruxolitinib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Carcinoma, Small Cell, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Mesothelioma
Interventions: Depsipeptide, Flavopiridol (alvocidib); Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Chronic Myelogenous Leukemia, Hematologic Malignancies
Interventions: Ponatinib; Drug
Lead sponsor: Ariad Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 5
States / cities: San Francisco, California • Ann Arbor, Michigan • Portland, Oregon + 2 more

Conditions: Ovarian Neoplasms
Interventions: Anetumab ravtansine (BAY94-9343), Pegylated Liposomal Doxorubicin; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 3
States / cities: Aurora, Colorado • New Haven, Connecticut • Oklahoma City, Oklahoma

Conditions: Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors
Interventions: NOX66, EBRT; Drug · Radiation
Lead sponsor: Noxopharm Limited; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Beverly Hills, California • Houston, Texas

Conditions: Hormone Refractory Prostate Cancer, Prostate Cancer
Interventions: L-377202; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older · Male only
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2001
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Ovarian Cancer
Interventions: CC-5013, topotecan; Drug
Lead sponsor: Celgene Corporation; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 3
States / cities: Augusta, Georgia • Minneapolis, Minnesota • Columbus, Ohio

Search by objective public record fields.

Actinium Therapy for Late-stage Aggressive Sarcomas

A Safety and Pharmacokinetic Study of TAK-285 in Patients With Advanced Cancer

Study to Determine the Safety, Maximum Tolerated Dose, Pharmacokinetics of Sorafenib (BAY43-9006)

Azacitidine Plus Phenylbutyrate in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Treatment

A First-in-human Study of Multiple Doses of BB-1701 in Subjects With Locally Advanced/Metastatic HER2 Expressing Solid Tumors

Phase 1 Study of BAY1905254 - An Early Clinical Research Study to Evaluate a New Drug Called Bapotulimab (BAY1905254) in the Expansion Cohort in Combination With Pembrolizumab in Head and Neck Cancer That Has Returned or is Discovered to be Metastatic and is Expressing PDL1.

Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug

Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 When Given Together With Chemotherapy and the Effectiveness of This Combination Treatment in Shrinking a Specific Type of Lung Tumors (Small Cell Lung Cancer)

Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma

A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors

Haploidentical Hematopoietic Stem Cell Transplantation Using A Novel Clofarabine Containing Conditioning Regimen For Patients With Refractory Hematologic Malignancies

Safety Study of ON 01910.Na in Combination With Irinotecan or Oxaliplatin

Paclitaxel Plus L-778,123 in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphomas

Study of Preoperative Radiation Therapy in Participants With Resectable Recurrent Abdominal Adrenocortical Carcinoma

Combination Chemotherapy in Treating Patients With Advanced Cancer

Double Blind, Placebo-controlled, Study of the Safety, Tolerability and Pharmacokinetics of AIN457 in Rheumatoid Arthritis Patients

Determine Maximum Tolerated Dose, Safety, and Tolerability of Rhenium (186Re) in Pediatric Recurrent, Refractory or Progressive Ependymoma and High-Grade Glioma

Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Depsipeptide/Flavopiridol Infusion for Cancers of the Lungs, Esophagus, Pleura, Thymus or Mediastinum

Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological Malignancies

Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant Cancer

A Study of NOX66 and External Beam Radiotherapy in Patients With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors

Study Evaluating the Safety and Tolerability of L-377202

Study of Lenalidomide With Topotecan In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma